N-Site is a free portal for Life Sciences companies where you can find a range of technical guidance notes on tax, legal and patent & trademark matters that impact the industry. Established by FTI Consulting in 2016 and developed in association with MedCity and the BioIndustry Association (BIA), the vision is that N-Site will become a primary resource for Expert Guidance for Life Sciences.
FTI Consulting’s European Tax Advisory practice comprises a wide range of leading industry specialisms one of which is a unique team supporting Life Sciences.
With a dedicated sector focus, FTI Consulting has been able to develop a number unique offerings for Life Sciences companies to support them in a range of tax matters including licensing, enhancing R&D tax reliefs, pharmaceutical transfer pricing and advanced tax modelling for financial forecasting.
Life Sciences is one of the most innovative and complex market sectors. It is currently undergoing a period of intense transformation, with companies facing an ever-increasing level of regulation as well as strict cost management in order to remain competitive and profitable.
Taylor Wessing’s Life Sciences team is widely regarded as one of the market leaders, providing a distinct legal service to pharmaceutical, biotech, medical device, diagnostics and research tool companies, as well as service providers in this sector.
The firm advises start-ups to major multinational organisations on every aspect of the product life cycle, from discovery and development through to end-of-life patent disputes.
It’s recognition is based on the extensive international expertise the group has in advising across the full range of areas that are central to the business of any life sciences company, including patent litigation, fund formation, venture capital, regulatory advice and licensing.
Gill Jennings & Every
GJE is a leading intellectual property firm based in London and Munich. They provide the ideal combination of legal, technical and commercial expertise to help turn innovations, brands and designs into commercial success.
They understand the importance of intellectual property to Life Sciences businesses and by providing clear, creative and expert advice they can assist in protecting, exploiting and managing IP assets to maximise their value.
GJE offers unique consultancy services, known as ConsultIP™, that benefit Life Sciences businesses at every stage of their life cycle – from developing and implementing an IP strategy, to ensuring they are due diligence ready, either to attract investment or secure an exit.
GJE are consistently recognised by the leading UK legal directories – Chambers, Legal 500 and Managing Intellectual Property – as a ‘go-to’ firm, which is a testament to the quality of their advice and the valued role they play in supporting their clients.
MedCity is a collaboration between the Mayor of London and the capital’s three Academic Health Science Centres – Imperial College Academic Health Science Centre, King’s Health Partners, and UCL Partners. Launched in April 2014 to promote and grow the UK’s world-leading life sciences clusters, it is promoting life sciences investment, entrepreneurship and industry in the region by:
- Providing a single front door and concierge service for industry and investors looking for partners, infrastructure and expertise
- Facilitating and supporting collaboration across all parts of the sector to turn innovations into commercial products and services
- Fostering an environment that supports and encourages entrepreneurialism
- Raising awareness globally of the region’s rich life sciences ecosystem
It is supported by the Higher Education Funding Council for England and the Mayor of London and works with academics, research and NHS institutions, as well as local enterprise partnerships and the Mayor’s official promotional organisation London & Partners.
BioIndustry Association (BIA)
The BIA is the trade association for innovative enterprises involved in UK bioscience. BIA’s goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.
BIA’s members are responsible for over 90% of biotech medicines currently in clinical development in the UK. In the last year, BIA members have taken forward pioneering research such as the first stem cell therapy clinical trials for stroke and the first drug to delay bone metastases in cancer.
The BIA pushes for progress in UK bioscience on every front. Their goal is to deliver the best possible environment for growth and innovation.
Register to receive up-to-date information and advice on tax and law developments within your industry.